Healthcare
Cosmo Pharmaceuticals NV(CMOPF)
Live Price
Offline$83.00
-5.95% today
1Y Change
+28.94%
Window
Jun 25, 2025 β Jun 18, 2026
- Market Cap
- $1.35B
- Revenue Growth
- -60.7%
- EPS Growth
- -102.8%
- Dividend Yield
- 2.5%
Coverage: 250 bars Β· Jun 25, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cosmo Pharmaceuticals NV (CMOPF) is a Healthcare stock with a market cap of $1.35B and listed on OTC. The stock last traded around $83.00 and up 28.9% across the available one-year price window (Jun 25, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of -60.7%, EPS growth of -102.8%, a dividend yield of 2.5%. What stands out right now is revenue -60.7%, EPS -102.8%, free cash flow -110.1% with operating margin -5.5% and ROIC -1.0%. The dividend matters to the case here, with a current yield around 2.5%. Valuation already assumes a fairly strong business story at price/sales 13.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CMOPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-60.7% vs +7.6% peer median
Operating Margin
Below sector median
-5.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 9, 2026 with an EPS surprise of -400.0% and a revenue surprise of 0.0%.
The operating picture looks softer than before
Revenue is at -60.7% and EPS is at -102.8%, with operating margin around -5.5%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 20, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 9, 2026 | -400.0% | +5.0% | -11.7% | -11.0% |
2025 Jul 23, 2025 | β | +0.0% | +16.5% | +16.5% |
2025 Mar 6, 2025 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CMOPF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CMOPF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CMOPF Max Drawdown
-50.72%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CMOPF and SPY.
Company Overview
Cosmo Pharmaceuticals NV
OTC
Cosmo Pharmaceuticals N.V. is a pharmaceutical company specializing in the development and commercialization of innovative products for gastroenterology, dermatology, and health technology worldwide. Its portfolio includes GI Genius, an AI-powered computer-assisted system for real-time detection of colorectal lesions during colonoscopies; Winlevi, a topical prescription treatment for acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet for inducing remission in mild to moderate ulcerative colitis; and Uceris/Cortiment, an oral budesonide formulation targeting the colon. Additional offerings encompass Eleview for safer gastrointestinal lesion excision, Lumeblue for enhanced lesion visualization, Aemcolo/Relafalk for travelers' diarrhea, and Byfavo, an intravenous sedative. The company advances a robust pipeline, including Breezula in Phase III trials as a scalp androgen receptor inhibitor for hair loss, Rifamycin enema in Phase II for ulcerative colitis, and early-stage candidates like Colesevelam for bile acid diarrhea and Cortexolone derivatives for solid tumors. Headquartered in Dublin, Ireland, and founded in 1997, Cosmo Pharmaceuticals N.V. partners globally with entities like Medtronic and Bausch Health to distribute its specialized therapies, playing a key role in addressing unmet needs in digestive health, skin conditions, and endoscopic diagnostics.
- Leadership
- Mr. Giovanni Di Napoli
- Employees
- 324
- Street Address
- Riverside 2, 49 Sir John Rogersonβs Quay Grand Canal Dock
- Mailing
- Dublin, MI, D02 KV60
- Region
- Dublin, MI, Ireland
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- 184.4
- Price/Sales
- 13.0
- Price/Book
- 2.8
Growth
- Revenue
- -60.7%
- EPS
- -102.8%
- Free Cash Flow
- -110.1%
Profitability
- Gross Margin
- 48.5%
- Operating Margin
- -5.5%
- Net Margin
- -3.5%
- ROE
- -0.8%
- ROIC
- -1.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 7.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.